Clinical Trial

Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery

Study acronym: RIPCORD
Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to characterize the reduction in PSMA-avid tumor volume and metastasis-directed radiotherapy treatment intensity facilitated by PET PSMA-response adapted SABR for poly-metastatic castration sensitive prostate cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-24.
Trial Details
NCT Number NCT07674771
Lead Sponsor University of Texas Southwestern Medical Center
Collaborators: Varian, a Siemens Healthineers Company, Telix Pharmaceuticals (Innovations) Pty Ltd
Conditions Prostate Cancer, Castration Sensitive Prostate Cancer, Metastatic Prostate Cancer, Adaptive Radiotherapy
Enrollment 30 participants
Start Date 2026-07-15
Primary Completion 2029-06-15 (estimated)
Study Completion 2029-06-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-23